Identification of eight virus will pave the way for the development of vaccine or one type of cancer the most common cancer of women in the world and killed an estimated 328,000 people in 2010. In large-scale research for 60 years by examining 10,575 cases of cervical cancer in 38 countries, groups of scientists led by Silvia de San Jose of the Catalan Institute of Oncology in Barcelona analyze various types of HPV that most often trigger cervical cancer.
The results of studies, published medical journal The Lancet, showed that eight HPV types namely types 16, 18, 45, 33, 31, 52, 58, and 35 (sorted by the type of the most influential) ‘responsible’ for more than 90 percent cases of cervical cancer.
So far, two major companies that GlaxoSmithKline (GSK) and Merck & Co. has created the HPV vaccine. Cervarix vaccine made by GSK and Merck’s Gardasil output capable of preventing HPV types 16 and 18, and through cross-protection can also protect against types 31 and 45.
Many rich nations started the HPV immunization program by injecting women before they reach the age of puberty, but in general the vaccine is still expensive and not accessible to women in poor countries. San Jose says, these findings confirm the importance of reasons for cervical cancer prevention through vaccines that exist today and help the development of second generation vaccines against many other HPV types.
About 80 percent of cases of cervical neck cancer is currently occurring in developing countries and the disease caused by a virus transmitted through high-risk sexual behavior.
Of the 118 HPV types identified by scientists, approximately 40 types infect the genital and 12 other types which are known to cause cancer. In a study of cancer cases in Europe, North America, South America the middle, Africa, Asia, and Oceania, the researchers also have identified several rare types such as HPV types 26, 30, 61, 67, 69, 82, and 91 – which would also cause cervical cancer, but only causes about one percent of all cases.